Boston Scientific posts strong Q2 growth despite U.S. challenges, stock now valued attractively.
Boston Scientific reported solid Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth, driven by strong international demand, particularly in electrophysiology and WATCHMAN devices. Despite facing growth headwinds in the U.S., the com...
